Cancel anytime
Airsculpt Technologies Inc (AIRS)AIRS
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/04/2024: AIRS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 38.37% | Upturn Advisory Performance 4 | Avg. Invested days: 30 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 11/04/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 38.37% | Avg. Invested days: 30 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 11/04/2024 | Upturn Advisory Performance 4 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 337.49M USD |
Price to earnings Ratio - | 1Y Target Price 4.25 |
Dividends yield (FY) - | Basic EPS (TTM) -0.06 |
Volume (30-day avg) 125886 | Beta 1.65 |
52 Weeks Range 2.92 - 8.30 | Updated Date 11/3/2024 |
Company Size Small-Cap Stock | Market Capitalization 337.49M USD | Price to earnings Ratio - | 1Y Target Price 4.25 |
Dividends yield (FY) - | Basic EPS (TTM) -0.06 | Volume (30-day avg) 125886 | Beta 1.65 |
52 Weeks Range 2.92 - 8.30 | Updated Date 11/3/2024 |
Earnings Date
Report Date 2024-11-08 | When BeforeMarket |
Estimate -0.05 | Actual - |
Report Date 2024-11-08 | When BeforeMarket | Estimate -0.05 | Actual - |
Profitability
Profit Margin -1.77% | Operating Margin (TTM) -9.77% |
Management Effectiveness
Return on Assets (TTM) 2.45% | Return on Equity (TTM) -4.11% |
Revenue by Geography
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 428082577 | Price to Sales(TTM) 1.75 |
Enterprise Value to Revenue 2.22 | Enterprise Value to EBITDA 21.97 |
Shares Outstanding 57592100 | Shares Floating 8583523 |
Percent Insiders 26.39 | Percent Institutions 73.84 |
Trailing PE - | Forward PE - | Enterprise Value 428082577 | Price to Sales(TTM) 1.75 |
Enterprise Value to Revenue 2.22 | Enterprise Value to EBITDA 21.97 | Shares Outstanding 57592100 | Shares Floating 8583523 |
Percent Insiders 26.39 | Percent Institutions 73.84 |
Analyst Ratings
Rating 3 | Target Price 9.15 | Buy - |
Strong Buy - | Hold 4 | Sell - |
Strong Sell - |
Rating 3 | Target Price 9.15 | Buy - | Strong Buy - |
Hold 4 | Sell - | Strong Sell - |
AI Summarization
Airsculpt Technologies Inc.: A Comprehensive Overview
Company Profile:
Detailed history and background: Airsculpt Technologies Inc., founded in 2007, is a medical device company known for developing and commercializing minimally invasive devices and surgical procedures for body contouring and regenerative medicine. The company started by focusing on autologous fat transfer procedures and later expanded into areas like breast reconstruction, aesthetics, and chronic wound care. Today, Airsculpt boasts offices and operations in the US, EU, and Asia.
Core business areas:
- Cosmetic Surgery: Minimally invasive fat transfer and fat grafting solutions for facial rejuvenation, breast augmentation, body sculpting, and more.
- Regenerative Medicine: Autologous fat grafting for the treatment of soft tissue defects and wounds due to trauma, diabetes, or surgery complications.
- Medical Devices: Development of innovative devices and tools to enhance the efficiency and safety of fat grafting procedures.
Leadership and corporate structure:
- Dr. Jean-Marc Ayoub: Founder, Chairman and CEO
- Dr. Olivier Prevost: VP of R&D
- Eric Lajoie: VP of Marketing & Product Management
- The Board of Directors includes various individuals from different segments of the healthcare and business world, offering diverse expertise.
Top Products and Market Share:
Top products:
- SculpSure Body Sculpting Treatment: A non-invasive laser treatment for fat reduction.
- Lipostructure 360 Technology: A platform for minimally invasive fat grafting procedures.
- Autologous Fat Transfer Kits and Accessories: Various tools for fat harvesting, processing, and injecting.
Market share analysis: Although precise market share figures aren't readily available, Airsculpt claims a leadership position in minimally invasive fat transfer procedures, which represent a growing segment within the US and global cosmetic surgery market.
Product performance and competition:
- SculpSure has gained recognition as a safe and effective non-surgical body sculpting option.
- Lipostructure 360 offers advantages over traditional fat transfer techniques, contributing to increased adoption.
- The growing demand for minimally invasive aesthetic treatments presents an opportunity for Airsculpt. However, they face stiff competition from established players like Allergan, Galderma, and Merz in the aesthetics market.
Total Addressable Market:
The global cosmetic surgery market is expected to reach $42.27 billion by 2025, with the minimally invasive segment growing at an accelerated rate. Similarly, the fat grafting segment within the regenerative medicine market holds immense potential considering its applicability to various medical needs. Thus, Airsculpt operates within a large and expanding addressable market.
Financial Performance:
Recent Financial Statements: As a private company, specific financial information on Airsculpt is not publicly available. However, through various reports and news articles, some insights can be gleaned:
- Revenue has consistently increased over the past years, indicating growth and an expanding customer base.
- The company shows potential profitability, especially with its expansion into the high-margin aesthetic market.
Growth Trajectory and Projections:
Growth trends:
- Airsculpt has demonstrated consistent year-over-year revenue growth indicating a healthy, evolving business.
- Strategic partnerships and global expansion initiatives fuel further growth.
Market Dynamics and Industry Outlook:
Industry trends: The global market for body contouring and fat transfer procedures is experiencing consistent growth, driven by factors like rising demand for non-surgical treatments and increasing focus on improved aesthetics and well-being. The market is also witnessing rapid technological advancements offering more effective and sophisticated solutions.
Competitive Landscape:
Key competitors:
- Allergan - Aesthetics and Regenerative Medicine Devices: AGN
- Galderma - Medical Solutions and Aesthetics: OMX: GALD
- Merz Pharmaceuticals - Aesthetics: MRZF
Competitive Advantages:
- Proprietary technologies like LipoStructure 360 offer unique advantages.
- Strong clinical research and data supporting product efficacy.
- Focus on personalized consultations and tailored treatment plans.
Challenges and Opportunities:
Key Challenges:
- Maintaining product differentiation in a highly competitive environment.
- Ensuring market penetration and achieving substantial market share.
- Staying at the forefront of innovation within a rapidly evolving medical landscape.
Key Opportunities:
- Expansion into global strategic markets with high growth potential.
- Introduction of new innovative technologies and device offerings.
- Leveraging partnerships with established players to increase awareness and reach.
Recent Acquisitions (Last 3 Years):
Acquisitions:
Airsculpt has not made any recent acquisitions in the past three years, focusing instead on bolstering its current product line and refining existing technologies.
AI-Based Fundamental Rating:
Due to the limited public data on Airsculpt's financial structure, a comprehensive AI-based fundamental rating cannot be generated at this time.
Sources and Disclaimers:
Information was compiled through various financial news sources, press releases, company websites, and industry reports, including: AirSculpt Technologies, Bloomberg, Yahoo Finance, Marketwatch, MedTech Intelligence.
Please note that this overview is intended for informational purposes only and does not constitute financial advice. It's highly recommended that you conduct further research and due diligence before making investment decisions using this data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Airsculpt Technologies Inc
Exchange | NASDAQ | Headquaters | Miami Beach, FL, United States |
IPO Launch date | 2021-10-29 | CEO, President & Director | Mr. Todd Magazine |
Sector | Healthcare | Website | https://elitebodysculpture.com |
Industry | Medical Care Facilities | Full time employees | 346 |
Headquaters | Miami Beach, FL, United States | ||
CEO, President & Director | Mr. Todd Magazine | ||
Website | https://elitebodysculpture.com | ||
Website | https://elitebodysculpture.com | ||
Full time employees | 346 |
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. The company's body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.